Recent research on a new type of omega-3 fatty acid suggests it may have the potential to prevent vision loss in diseases such as age-related macular degeneration (AMD), Alzheimer’s disease, diabetes, and retinitis pigmentosa (RP).
Give me some background first.
The omega-3 fatty acid docosahexaenoic acid (DHA) is typically found in fish oil capsules and other supplements in a form called triacylglycerol (TAG) DHA.
However, TAG-DHA cannot reach the eyes due to its inability to overcome the blood-retina barrier. Thus, DHA deficiency in the retina is associated with vision loss.
Now talk about this research.
Researchers developed a new lysophospholipid form of DHA— known as LPC-DHA—that is able to be absorbed into the bloodstream from the intestines, and then penetrate the retina, resulting in improved retinal function.
How about the study?
The LPC-DHA supplement was tested in mice that were bred to exhibit processes similar to that found in early-onset Alzheimer’s disease. The mice received a daily dosage (equivalent to approximately 250 to 500 milligrams for humans) for 6 months.
Results?
After 6 months of daily dosing, the LPC-DHA-treated mice exhibited a 96% improvement in retinal DHA content along with preserved retinal structure and function.
Comparatively, TAG-DHA supplements had no effect on retinal DHA levels or function.
Limitations?
Current information on the study does not specify the number of mice involved nor whether all or some mice received TAG-DHA supplements.
Significance?
Researchers suggest these findings support the use of LPC-DHA supplements in preventing Alzheimer’s-related visual function declines as well as in other similar neurodegenerative diseases involving DHA deficiency and vision impairment.
However, they recommend that further studies are needed to confirm LPC-DHA is as safe and effective in humans as it is in mice.